Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: Novel chemotherapeutic targets in pancreatic endocrine tumors

American Journal of Gastroenterology

Volumn 104, Issue 1, 2009, Pages 171-181

  Bergmann, Frank ^a   Breinig, Marco ^a   Höpfner, Michael ^b   Rieker, Ralf J ^a,c   Fischer, Lars ^a   Köhler, Christian ^a   Esposito, Irene ^a   Kleeff, Jörg ^a,d   Herpel, Esther ^a   Ehemann, Volker ^a   Friess, Helmut ^a,d   Schirmacher, Peter ^a   Kern, Michael A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GASTRIN; GLUCAGON; INSULIN; SEROTONIN; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TYRPHOSTIN;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORPHOLOGY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TARGETING; ENDOCRINE TUMOR; FEMALE; FUNCTION TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS CELL; PANCREAS ISLET CELL TUMOR; PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TREATMENT RESPONSE; ANIMAL; CARCINOID; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOID TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULINOMA; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PANCREATIC NEOPLASMS; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TUMOR CELLS, CULTURED; TYRPHOSTINS; YOUNG ADULT;

EID: 60749086869     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.33     Document Type: Article

References (52)

1. Heitz PU, Komminoth P, Perren A et al. Pancreatic endocrine tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Tumours of Endocrine Organs: Pathology and Genetics. World Health Organisation Classification of Tumors. IARC Press: Lyon, 2004.
2. Fischer L, Kleeff J, Esposito I et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627-35.
3. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92.
4. Kirshbom PM, Kherani AR, Onaitis MW et al. Foregut carcinoids: a clinical and biochemical analysis. Surgery 1999;126:1105-10.
5. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006;141:765-9.
6. Plöckinger U, Wiedenmann B. Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:553-76.
7. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
8. Duran I, Salazar R, Casanovas O et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007;18:1307-13.
9. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett 2007;251:237-46.
10. Reckamp KL, Krysan K, Morrow JD et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006;12:3381-8.
11. Kern MA, Haugg AM, Koch AF et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006;66:7059-66.
12. Kern MA, Schoneweiss MM, Sahi D et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004;25:1193-9.
13. Ali S, El-Rayes BF, Sarkar FH et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005;4:1943-51.
14. Lanza-Jacoby S, Burd R, Rosato FE Jr et al. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res 2006;12:6161-9.
15. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
16. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
17. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 2007;19:98-102.
18. Höpfner M, Sutter AP, Gerst B et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD 1839). Br J Cancer 2003;89:1766-75.
19. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005;18:1329-35.
20. Srivastava A, Alexander J, Lomakin I et al. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol 2001;32:1184-9.
21. Peghini PL, Iwamoto M, Raffeld M et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002;8:2273-85.
22. Okami J, Nakamori S, Yamamoto H et al. An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas. J Exp Clin Cancer Res 2002;21:569-76.
23. Ohike N, Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol Int 2001;51:770-7.
24. Kern MA, Schubert D, Sahi D et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatol 2002;36:885-94.
25. Schmitt A, Anlauf M, Rousson V et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007;31:1677-82.
26. Ince AT, Ovünc O, Celikel CA, Göksel S, Tosun S, Peker O. Cycooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors. Hepatogastroenterol 2007;76:1125-9.
27. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathol 2008;52:738-46.
28. Efrat S, Linde S, Kofod H et al. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA 1988;85:9037-41.
29. Nicoletti I, Migliorati G, Pagliacci MC et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
30. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;4:1469-73.
31. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
32. Barton CM, Hall PA, Hughes CM et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111-6.
33. Dong M, Nio Y, Guo KJ et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18:4613-9.
34. Uegaki K, Nio Y, Inoue Y et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997;17:3841-7.
35. Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12.
36. Jardines L, Weiss M, Fowble B et al. neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993;61:268-82.
37. Jeon YK, Sung SW, Chung JH et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006;54:387-98.
38. Yang F, Bleich D. Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells. J Biol Chem 2004;279:35403-11.
39. Sorli CH, Zhang HJ, Armstrong MB et al. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci USA 1998;95:1788-93.
40. Schlosser W, Schlosser S, Ramadani M et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25:26-30.
41. Albazaz R, Verbeke CS, Rahman SH et al. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatol 2005;5:361-9.
42. Kokawa A, Kondo H, Gotoda T et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-8.
43. Molina MA, Sitja-Arnau M, Lemoine MG et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59: 4356-62.
44. Cho BC, Im CK, Park MS et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33.
45. Feld R, Sridhar SS, Shepherd FA et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol 2006;1: 367-76.
46. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25:2178-83.
47. Zampino MG, Magni E, Massacesi C et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007;110:752-8.
48. Souglakos J, Kalykaki A, Vamvakas L et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007;18:305-10.
49. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-74.
50. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
51. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
52. Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. Am J Clin Oncol 2003;26:S110-3.